Ophthotech gains gene therapy for orphan vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) gained $0.29 (10%) to $3.09 on Thursday on news that it acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research

Read the full 333 word article

How to gain access

Continue reading with a
two-week free trial.